儿童T细胞急性淋巴细胞白血病单倍体造血干细胞移植后复发结局及相关预后因素
该回顾性队列纳入2010年1月至2022年6月间128例接受单倍体造血干细胞移植的儿童T细胞急性淋巴细胞白血病患者,2年总生存率和无白血病生存率分别为67.77%±4.21%和66.34%±3.82%,累积复发率33.82%±0.70%,非复发死亡率12.65%±0.46%。多因素Cox回归显示CD34细胞、移植前微小残留病≥0.01%、慢性移植物抗宿主病和巨细胞病毒与复发相关(p<0.05)。
要点
- 儿童T-ALL单倍体移植后2年累积复发率为33.82%±0.70%,长期生存较差。
- 移植前MRD≥0.01%、CD34细胞、cGvHD和巨细胞病毒与复发相关(p<0.05)。
- 低分组(0-2分)与高分组(3、4分)2年累积复发率分别为23.76%±1.83%和48.22%±2.42%(p=0.009)。
核心结论
- 儿童T-ALL长期生存较差,单倍体造血干细胞移植是有效且安全的治疗,但复发率较高。
- 清除移植前MRD、保证足够的CD34细胞输注以及发生cGvHD和巨细胞病毒再激活可能有利于减少复发。
研究设计与样本
- 回顾性连续队列研究,纳入2010年1月至2022年6月间2642例连续ALL患者中的128例接受单倍体造血干细胞移植的儿童T-ALL患者。
主要发现
- 2年总生存率为67.77%±4.21%,无白血病生存率为66.34%±3.82%。
- 累积复发率为33.82%±0.70%,非复发死亡率为12.65%±0.46%。
- 多因素Cox回归分析显示CD34细胞、移植前MRD≥0.01%、cGvHD和巨细胞病毒与复发相关(p<0.05)。
- 低分组(0-2分)与高分组(3、4分)的2年累积复发率分别为23.76%±1.83%和48.22%±2.42%(p=0.009)。
关键数值与推荐
- 评分系统将患者分为低分组(0-2分)和高分组(3、4分)。
- 低分组2年累积复发率为23.76%±1.83%,高分组为48.22%±2.42%(p=0.009)。
- 移植前MRD≥0.01%与复发相关(p<0.05)。
临床怎么用
- 原文结论指出,清除移植前MRD、保证足够的CD34细胞输注以及发生cGvHD和巨细胞病毒再激活可能有利于减少复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The outcomes are poor for paediatric patients with T-cell acute lymphoblastic leukaemia (T-ALL) who relapse after haematopoietic stem cell transplantation (HSCT). However, studies focusing on paediatric patients with T-ALL following haploidentical HSCT (haplo-HSCT) are limited. We retrospectively identified a consecutive cohort comprising of 128 paediatric T-ALL after haplo-HSCT from 2642 consecutive ALL patients between January 2010 and June 2022. The 2-year overall survival and leukaemia-free survival were 67.77% ± 4.21% and 66.34% ± 3.82%, respectively, and the cumulative incidence of relapse (CIR) and non-relapse mortality were 33.82% ± 0.70% and 12.65% ± 0.46% respectively. According to the multivariate Cox regression analysis, CD34 cells, minimal residual disease (MRD) ≥0.01% before HSCT, chronic graft-versus-host disease (cGvHD) and cytomegalovirus were associated with relapse (p < 0.05). To develop a scoring system for stratifying patients, we combined the variables and stratified them into low (0-2 points) and high (3, 4) groups. Consequently, the 2-year CIR in low and high groups were 23.76% ± 1.83% and 48.22% ± 2.42% (p = 0.009), respectively. Children with T-ALL have poor long-term survival, and haplo-HSCT is a potent and safe treatment; however, the incidence of relapse is high. Eliminating pre-HSCT MRD, guaranteeing sufficient CD34 cells infusion and the occurrence of cGvHD and cytomegalovirus reactivation may benefit from relapse.
引用
- Zhao C, Xiao MY, Zhang F, et al. Outcomes and prognostic factors associated with relapse after haploidentical stem cell transplantation for paediatric T-cell acute lymphoblastic leukaemia. Br J Haematol. 2025. PMID: 39994922. doi:10.1111/bjh.20007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。